Related Experiment Video

Updated: Jul 14, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Analysis of antihypertensive effects of statins

Haralampos J Milionis1, Evagelos N Liberopoulos, Moses S Elisaf

  • 1Department of Clinical Biochemistry, Vascular Disease Prevention Clinics, Royal Free Hospital, Pond Street, London NW3 2QG, UK.

Current Hypertension Reports
|May 24, 2007
PubMed

Insights

Statins, used for high cholesterol, also lower blood pressure (BP) through mechanisms beyond lipid reduction. This BP reduction may offer additional cardiovascular disease (CVD) benefits, especially in hypertensive patients.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Hypertension and hyperlipidemia are major cardiovascular disease (CVD) risk factors that frequently coexist.
  • Statins are primary treatments for hyperlipidemia, offering significant CVD risk reduction.
  • Emerging evidence suggests statins may also lower blood pressure (BP).

Purpose of the Study:

  • To explore the potential blood pressure-lowering effects of statins.
  • To investigate if statin-induced BP reduction is independent of lipid-lowering effects.
  • To assess the clinical relevance of statins in managing hypertension.

Main Methods:

  • Review of clinical and experimental evidence on statin effects on blood pressure.
  • Analysis of data from large landmark studies involving statins and hypertensive patients.

Main Results:

  • Statins demonstrate a capacity to modulate blood pressure (BP).
  • The BP-lowering mechanisms of statins appear independent of their lipid-modifying effects.
  • Studies confirm statins reduce CVD risk in hypertensive individuals.

Conclusions:

  • Statin-induced BP reduction, though small, may be clinically significant.
  • Statins could serve as an adjunctive therapy for hypertension, particularly in patients with dyslipidemia or normal cholesterol.
  • Further large-scale trials are needed to confirm additional clinical outcome benefits from statin-mediated BP reduction.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...